CG Pharmaceuticals, Inc.
🇺🇸United States
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
Phase 1
Recruiting
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- CG Pharmaceuticals, Inc
- Target Recruit Count
- 70
- Registration Number
- NCT05249101
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Hoag Medical Group, Newport Beach, California, United States
🇺🇸UCSF Medical Center, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath